Welcome to our dedicated page for Ngm Biopharmaceuticals news (Ticker: NGM), a resource for investors and traders seeking the latest updates and insights on Ngm Biopharmaceuticals stock.
NGM Biopharmaceuticals, Inc. (NGM) has described itself as a biotechnology company focused on discovering and developing novel, life-changing medicines, with all product candidates generated by its in-house discovery engine. The NGM Bio news flow reflects this biology-centric strategy across oncology, liver disease and rare conditions, as well as significant corporate developments affecting the former NGM stock listing.
News coverage for NGM Bio includes updates on its solid tumor oncology programs, such as clinical data from the ongoing Phase 1/2 trial of NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, in combination with KEYTRUDA (pembrolizumab) in advanced or metastatic solid tumors. The company has also reported progress on NGM831 and NGM438, antagonist antibody product candidates targeting ILT3 and LAIR1, respectively, in combination with pembrolizumab.
Investors and observers can also find news items detailing NGM Bio’s work in liver and metabolic diseases, including positive Phase 2b results from the ALPINE 4 trial of aldafermin, an engineered FGF19 analog, in patients with compensated cirrhosis due to NASH, and plans to further develop aldafermin for primary sclerosing cholangitis. Additional updates have covered the potential development of NGM120, a GDF15/GFRAL antagonist antibody product candidate, for hyperemesis gravidarum, a rare and serious pregnancy-related condition.
Another important theme in NGM Bio news is corporate and transaction activity. The company announced an Agreement and Plan of Merger with Atlas Neon Parent, Inc. and Atlas Neon Merger Sub, Inc., affiliates of The Column Group, LP, followed by the closing of a cash tender offer and subsequent merger that resulted in NGM Bio becoming a privately held, wholly-owned subsidiary and its common stock ceasing to trade on Nasdaq.
By reviewing the NGM news feed, readers can track historical announcements on clinical data presentations, conference participation, strategic updates on pipeline prioritization, and the steps that led to the going-private transaction. This provides context on how NGM Bio’s scientific programs and corporate structure have evolved over time.
NGM Biopharmaceuticals (NGM) provided an overview of its 2022 highlights and 2023 priorities. The three-pronged strategy emphasizes clinical development in solid tumor oncology, generating next-generation biologics, and forming partnerships for various programs, including aldafermin and NGM621. Notably, the company aims to advance its myeloid checkpoint inhibitor programs, NGM707, NGM831, and NGM438, into further clinical trials in 2023. NGM Bio's cash resources are projected to fund operations into Q4 2024, supporting its focus on developing transformative therapeutics.
Belharra Therapeutics has launched a next-generation chemoproteomics platform, emerging from stealth with $130 million in funding. This includes $50 million in Series A financing led by Versant Ventures and an $80 million collaboration with Genentech. The platform allows for the identification of small molecule drug candidates across all protein targets, enhancing drug discovery potentials beyond traditional methods. With a focus on oncology and immunology, Belharra aims to develop therapeutics for challenging conditions.
NGM Biopharmaceuticals (NGM) presented new findings on NGM936, a bispecific T cell engager targeting ILT3 in acute myeloid leukemia (AML), at the ASH Annual Meeting. NGM936 showed potent T cell-dependent cytotoxicity against ILT3+ AML cells while minimizing cytokine release. With ILT3 specificity, it promises targeted treatment for monocytic AML, a subtype with poor prognosis, accounting for 25-30% of AML cases. NGM Bio plans to seek a partner for clinical development in hematologic oncology.
NGM Biopharmaceuticals presented preliminary data on NGM707 at the ESMO I-O Annual Congress, showing it was generally well tolerated up to 1800 mg with no maximum tolerated dose reached. The drug demonstrated linear pharmacokinetics at doses ≥200 mg and early anti-tumor activity in a Phase 1 trial involving 34 patients with various solid tumors as of November 23, 2022. Notably, there were partial responses in one patient and stable disease in six others, with some patients experiencing significant tumor size reductions, including a 70% decrease. Ongoing enrollment aims to expand effective treatment.
NGM Biopharmaceuticals (NASDAQ: NGM) announced that preliminary data from its Phase 1a study of NGM707, an ILT2/ILT4 dual antagonist antibody, will be presented at the ESMO I-O Annual Congress on December 8, 2022. The ongoing trial focuses on patients with advanced solid tumors expressing ILT2 and ILT4. NGM707 aims to reprogram suppressive cells in the tumor microenvironment to encourage anti-tumor immunity. The company plans to enroll approximately 220 patients in this study, which is part of its wider oncology portfolio.
NGM Biopharmaceuticals (NGM) announced the acceptance of an abstract for their bispecific T-cell engager program, NGM936, at the ASH Annual Meeting from December 10-13, 2022. The presentation will cover NGM936's potential in treating ILT3-positive acute myeloid leukemia and multiple myeloma. Dr. Fabiana Perna from Indiana University will present research supporting NGM936's efficacy. The company emphasizes its focus on developing transformative therapies and currently has seven clinical programs, with four in advanced phases.
NGM Biopharmaceuticals reported disappointing results from the Phase 2 CATALINA trial of NGM621 for geographic atrophy, failing to meet its primary endpoint. Updated findings from Phase 1 trials of NGM120 for cancer were shared at prestigious conferences. Financially, the company posted a net loss of $47.3 million for Q3 2022, up from a $28.9 million loss in Q3 2021. Revenue from collaborations decreased significantly, and R&D expenses rose to $46.1 million, driven by ongoing clinical trials. NGM Bio holds $300.2 million in cash, projected to fund operations until Q4 2024.
NGM Biopharmaceuticals (NGM) recently shared findings from the post-hoc analyses of its Phase 2 CATALINA trial for NGM621, aimed at treating geographic atrophy (GA) due to age-related macular degeneration (AMD). The trial's primary endpoint was the change in GA lesion area over 52 weeks. Although initial results showed a 6.3% and 6.5% reduction in lesion area for different dosing schedules, these did not reach statistical significance. However, post-hoc evaluations revealed a promising 21.9% and 16.8% reduction in specific patient subgroups, indicating potential for further exploration.
NGM Biopharmaceuticals announced results from its CATALINA Phase 2 trial of NGM621 for geographic atrophy, revealing that the trial did not meet its primary endpoint of statistically significant reduction in GA lesion area over 52 weeks compared to sham treatment. NGM621 exhibited a favorable safety profile, showing no significant increase in choroidal neovascularization (CNV) and no treatment-related serious adverse events. Further analyses are set to be presented at The Retina Society Annual Scientific Meeting in November.
NGM Biopharmaceuticals, Inc. (NGM) will host a conference call on October 17, 2022, at 8:00 a.m. ET to discuss topline efficacy and safety results from the CATALINA Phase 2 trial of NGM621, targeting geographic atrophy due to age-related macular degeneration. The trial's results are crucial for understanding the potential therapeutic impact of NGM621 on this condition. Investors can access the live webcast and slides on the company's website, which will be archived for 30 days. NGM continues to develop seven clinical programs across various therapeutic areas.